Literature DB >> 23847220

Myelodysplastic syndromes: clinical practice guidelines in oncology.

Peter L Greenberg1, Eyal Attar, John M Bennett, Clara D Bloomfield, Uma Borate, Carlos M De Castro, H Joachim Deeg, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Steven D Gore, David Head, Rami Komrokji, Lori J Maness, Michael Millenson, Margaret R O'Donnell, Paul J Shami, Brady L Stein, Richard M Stone, James E Thompson, Peter Westervelt, Benton Wheeler, Dorothy A Shead, Maoko Naganuma.   

Abstract

The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disorders primarily affect older adults. The NCCN Clinical Practice Guidelines in Oncology for MDS provide recommendations on the diagnostic evaluation and classification of MDS, risk evaluation according to established prognostic assessment tools (including the new revised International Prognostic Scoring System), treatment options according to risk categories, and management of related anemia.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23847220      PMCID： PMC4000017          DOI： 10.6004/jnccn.2013.0104

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  112 in total

1.  Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes.

Authors:  Pilar Giraldo; Benet Nomdedeu; Javier Loscertales; Carmen Requena; Raquel de Paz; Mar Tormo; Pilar Navarro; Patricia Benedit; José Antonio Gasquet
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

Review 2.  Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.

Authors:  Peter Valent; Hans-Peter Horny; John M Bennett; Christa Fonatsch; Ulrich Germing; Peter Greenberg; Torsten Haferlach; Detlef Haase; Hans-Jochen Kolb; Otto Krieger; Michael Loken; Arjan van de Loosdrecht; Kiyoyuki Ogata; Alberto Orfao; Michael Pfeilstöcker; Björn Rüter; Wolfgang R Sperr; Reinhard Stauder; Denise A Wells
Journal:  Leuk Res       Date:  2007-01-25       Impact factor: 3.156

3.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Authors:  Hagop Kantarjian; Yasuhiro Oki; Guillermo Garcia-Manero; Xuelin Huang; Susan O'Brien; Jorge Cortes; Stefan Faderl; Carlos Bueso-Ramos; Farhad Ravandi; Zeev Estrov; Alessandra Ferrajoli; William Wierda; Jianqin Shan; Jan Davis; Francis Giles; Hussain I Saba; Jean-Pierre J Issa
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

4.  Hypocupremia associated with prior vitamin B12 deficiency.

Authors:  Calin I Prodan; Sylvia S Bottomley; Andrea S Vincent; Linda D Cowan; Neil R Holland; Stuart E Lind
Journal:  Am J Hematol       Date:  2007-04       Impact factor: 10.047

5.  Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.

Authors:  Hagop M Kantarjian; Susan O'Brien; Jianqin Shan; Ahmed Aribi; Guillermo Garcia-Manero; Elias Jabbour; Farhad Ravandi; Jorge Cortes; Jan Davisson; Jean-Pierre Issa
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

6.  Hypocupremia and bone marrow failure.

Authors:  A S Haddad; V Subbiah; A E Lichtin; K S Theil; J P Maciejewski
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

7.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Authors:  Azra Raza; James A Reeves; Eric J Feldman; Gordon W Dewald; John M Bennett; H Joachim Deeg; Luke Dreisbach; Charles A Schiffer; Richard M Stone; Peter L Greenberg; Peter T Curtin; Virginia M Klimek; Jamile M Shammo; Deborah Thomas; Robert D Knight; Michele Schmidt; Kenton Wride; Jerome B Zeldis; Alan F List
Journal:  Blood       Date:  2007-09-24       Impact factor: 22.113

Review 8.  Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.

Authors:  Luca Malcovati
Journal:  Leuk Res       Date:  2007-12       Impact factor: 3.156

9.  Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

Authors:  Sophie Park; Sophie Grabar; Charikleia Kelaidi; Odile Beyne-Rauzy; Françoise Picard; Valérie Bardet; Valérie Coiteux; Geneviève Leroux; Pascale Lepelley; Marie-Thérèse Daniel; Stéphane Cheze; Béatrice Mahé; Augustin Ferrant; Christophe Ravoet; Martine Escoffre-Barbe; Lionel Adès; Norbert Vey; Lina Aljassem; Aspasia Stamatoullas; Lionel Mannone; Hervé Dombret; Keith Bourgeois; Peter Greenberg; Pierre Fenaux; François Dreyfus
Journal:  Blood       Date:  2007-10-16       Impact factor: 22.113

10.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

Authors:  Luca Malcovati; Ulrich Germing; Andrea Kuendgen; Matteo G Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Aristoteles Giagounidis; Barbara Hildebrandt; Paolo Bernasconi; Sabine Knipp; Corinna Strupp; Mario Lazzarino; Carlo Aul; Mario Cazzola
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544
View more
  34 in total

1.  Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).

Authors:  M G Della Porta; H Tuechler; L Malcovati; J Schanz; G Sanz; G Garcia-Manero; F Solé; J M Bennett; D Bowen; P Fenaux; F Dreyfus; H Kantarjian; A Kuendgen; A Levis; J Cermak; C Fonatsch; M M Le Beau; M L Slovak; O Krieger; M Luebbert; J Maciejewski; S M M Magalhaes; Y Miyazaki; M Pfeilstöcker; M A Sekeres; W R Sperr; R Stauder; S Tauro; P Valent; T Vallespi; A A van de Loosdrecht; U Germing; D Haase; P L Greenberg; M Cazzola
Journal:  Leukemia       Date:  2015-02-27       Impact factor: 11.528

Review 2.  Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).

Authors:  Ehab Atallah; Kathryn Bylow; Jesse Troy; Wael Saber
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

3.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Authors:  David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert
Journal:  Blood       Date:  2015-04-30       Impact factor: 22.113

Review 4.  Standardizing the initial evaluation for myelodysplastic syndromes.

Authors:  Danielle Marshall; Gail J Roboz
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

5.  Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes.

Authors:  Naval Daver; Kiran Naqvi; Elias Jabbour; Tapan Kadia; Courtney DiNardo; Marylou Cardenas-Turanzas; Sherry Pierce; Khanh Thi-Thuy Nguyen; Carlos Bueso-Ramos; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2014-02-21       Impact factor: 10.047

6.  Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients.

Authors:  Daniel F Pease; Julie A Ross; Jenny N Poynter; Phuong L Nguyen; Betsy Hirsch; Adina Cioc; Michelle A Roesler; Erica D Warlick
Journal:  Cancer Epidemiol       Date:  2015-02-18       Impact factor: 2.984

Review 7.  Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

Authors:  Theo de Witte; David Bowen; Marie Robin; Luca Malcovati; Dietger Niederwieser; Ibrahim Yakoub-Agha; Ghulam J Mufti; Pierre Fenaux; Guillermo Sanz; Rodrigo Martino; Emilio Paolo Alessandrino; Francesco Onida; Argiris Symeonidis; Jakob Passweg; Guido Kobbe; Arnold Ganser; Uwe Platzbecker; Jürgen Finke; Michel van Gelder; Arjan A van de Loosdrecht; Per Ljungman; Reinhard Stauder; Liisa Volin; H Joachim Deeg; Corey Cutler; Wael Saber; Richard Champlin; Sergio Giralt; Claudio Anasetti; Nicolaus Kröger
Journal:  Blood       Date:  2017-01-17       Impact factor: 22.113

8.  Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients.

Authors:  Lisette Del Corso; Lucia Biale; Emanuele Luigi Parodi; Rodolfo Russo; Rosa Filiberti; Eleonora Arboscello
Journal:  Int J Clin Oncol       Date:  2016-10-22       Impact factor: 3.402

Review 9.  Improving Prognostic Modeling in Myelodysplastic Syndromes.

Authors:  Aziz Nazha; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

10.  Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.

Authors:  Dana E Rollison; Kenneth H Shain; Ji-Hyun Lee; Shalaka S Hampras; William Fulp; Kate Fisher; Najla H Al Ali; Eric Padron; Jeffrey Lancet; Qiang Xu; Martha Olesnyckyj; Laurie Kenvin; Robert Knight; William Dalton; Alan List; Rami S Komrokji
Journal:  Cancer Med       Date:  2016-04-20       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.